Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Magenta Therapeutics, Inc.
  6. Summary
    MGTA   US55910K1088

MAGENTA THERAPEUTICS, INC.

(MGTA)
  Report
Delayed Nasdaq  -  04:00:00 2023-03-24 pm EDT
0.7876 USD   +1.70%
03/23MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
03/21North American Morning Briefing: Stock Futures -2-
DJ
03/14North American Morning Briefing: CPI Print Takes -3-
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2023 03/21/2023 03/22/2023 03/23/2023 03/24/2023 Date
0.76(c) 0.7499(c) 0.75(c) 0.7744(c) 0.7876 Last
49 464 171 357 141 097 157 156 215 858 Volume
-1.14% -1.33% +0.01% +3.25% +1.70% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 - - -
Net income 2023 -28,7 M - -
Net Debt 2023 - - -
P/E ratio 2023 -1,66x
Yield 2023 -
Sales 2024 - - -
Net income 2024 -43,3 M - -
Net Debt 2024 - - -
P/E ratio 2024 -1,22x
Yield 2024 -
Capitalization 47,4 M 47,4 M -
Capi. / Sales 2023 -
Capi. / Sales 2024 -
Nbr of Employees 66
Free-Float 97,7%
More Financials
Company
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect... 
Read more
More about the company
Ratings of Magenta Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about MAGENTA THERAPEUTICS, INC.
03/23MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
03/21North American Morning Briefing: Stock Futures -2-
DJ
03/14North American Morning Briefing: CPI Print Takes -3-
DJ
03/07North American Morning Briefing: Stocks Seen on -2-
DJ
02/28HC Wainwright Initiates Magenta Therapeutics at Neutral
MT
02/07Magenta Therapeutics, Inc. : Results of Operations and Financial Condition, Costs Associat..
AQ
02/07Magenta Therapeutics, Inc. Announces Management Changes
CI
02/07Magenta Therapeutics, Inc. Announces the Resignation of Jason Gardner, Chief Executive ..
CI
02/03Rapid January Jobs Growth and Weak Tech Earnings Weigh on US Equity Futures
MT
02/03Top Premarket Gainers
MT
02/03North American Morning Briefing: Big Tech Disappointment to Drag on Nasdaq
DJ
02/02Stocks to Watch: Apple, Amazon.com, Alphabet, Magenta Therapeutics, Clorox
DJ
02/02Magenta Therapeutics, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing..
AQ
02/02Magenta Therapeutics to Explore Strategic Alternatives
AQ
01/26BTIG Downgrades Magenta Therapeutics to Neutral From Buy
MT
More news
News in other languages on MAGENTA THERAPEUTICS, INC.
02/07Magenta Therapeutics, Inc. annonce des changements de direction
02/07Magenta Therapeutics, Inc. annonce la démission de Jason Gardner, président-directeur g..
02/03La croissance rapide de l'emploi en janvier et la faiblesse des bénéfices des entrepris..
02/03Principaux gagnants du pré-marché
01/26Principales baisses du pré-marché
More news
Analyst Recommendations on MAGENTA THERAPEUTICS, INC.
More recommendations
ETFs positioned on MAGENTA THERAPEUTICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Micro-Cap ETF - USD0.01%-3.97%United_States
Vanguard Extended Market ETF - USD0%-2.10%United_States
Vanguard Total Stock Market ETF - USD0%0.38%United_States
Vanguard Total Stock Market ETF - USD0%-1.03%United_States
More ETFs positioned on MAGENTA THERAPEUTICS, INC.
Chart MAGENTA THERAPEUTICS, INC.
Duration : Period :
Magenta Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MAGENTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 0,79 $
Average target price 1,00 $
Spread / Average Target 27,0%
EPS Revisions
Managers and Directors
Stephen Frank Mahoney President, Chief Operating & Financial Officer
Alison Francis Lawton Chairman
Lisa M. Olson Chief Scientific Officer & Head-Research
Jeffrey S. Humphrey Chief Medical Officer
Bruce Lee Booth Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MAGENTA THERAPEUTICS, INC.99.39%47
REGENERON PHARMACEUTICALS, INC.11.18%85 611
VERTEX PHARMACEUTICALS5.53%78 349
WUXI APPTEC CO., LTD.-1.06%34 400
BIONTECH SE-13.87%31 444
GENMAB A/S-13.29%24 332
Stock markets for all
100% Free Registration
fermer